Summary
Pfizer Inc. announced a significant leadership transition, effective January 1, 2019. Albert Bourla, currently the Chief Operating Officer, has been appointed as the new Chief Executive Officer. Ian Read, the outgoing Chairman and CEO, will transition to the role of Executive Chairman. This move signals a planned succession and brings Bourla, who has held various leadership positions within the company including COO, to the helm. In conjunction with these appointments, new compensation arrangements have been disclosed for both executives. Dr. Bourla's base salary will increase to $1,600,000, and his target annual cash incentive opportunity will rise to $2,594,700. Mr. Read's compensation as Executive Chairman will include a base salary of $1,200,000 and an annual target cash incentive opportunity of $1,800,000. Investors should monitor how this new leadership structure influences Pfizer's strategic direction and operational execution moving forward.
Key Highlights
- 1Albert Bourla appointed Chief Executive Officer, effective January 1, 2019.
- 2Ian Read transitions from Chairman and CEO to Executive Chairman, effective January 1, 2019.
- 3Albert Bourla, the incoming CEO, has a deep background within Pfizer, including his recent role as Chief Operating Officer.
- 4Dr. Bourla's annual base salary will increase to $1,600,000.
- 5Dr. Bourla's annual target cash incentive opportunity will increase to $2,594,700.
- 6Ian Read's compensation as Executive Chairman will include a $1,200,000 base salary and a $1,800,000 target cash incentive opportunity.
- 7This filing confirms a planned leadership succession at the highest executive levels of the company.